Celularity, a biotech company specializing in placental-derived allogeneic cell therapies, will be showcasing data at the upcoming ASGCT Annual Meeting, showcasing the potential of their off-the-shelf natural killer (NK) cells to combat age-related diseases....
MaaT Pharma, a clinical-stage biotech company developing microbiome ecosystem therapies, has presented positive results from a recent study investigating its lead product MaaT013 for patients with steroid-refractory (SR) or steroid-dependent (SD) gastrointestinal...
The US investment firm Bioluminescence Ventures (BLV) has emerged from stealth with $477 million to finance biotech companies developing first-in-class or best-in-class disease treatments.
Around 25% of US venture capital biopharma investments flowed to Massachusetts in 2022: cementing the state’s position as a leader in the industry. But how will economic uncertainty affect the hub’s fortunes moving forward?
Unveiled at the 2022 BIO International Convention, the group's third annual diversity, equity, and inclusion report spotlights improvements both made and needed.
Fujifilm completed the acquisition of Biogen manufacturing site in Denmark for $890m in a cash transaction as it works to expand its global business lines.
Rosalind Franklin University of Medicine and Science opens its incubator, Helix 51, creating wet lab and research space for the Illinois bioscience hub.
Fujifilm Life Science Strategic Business Office will open a site in Cambridge, Massachusetts in an aim to further link up with the surrounding pharmaceutical and biotech community.
Diverse leadership provides more opportunity for innovation and higher performance in financial return, says diversity and inclusion chair and biotech executive.
CPhI North America donates $10,000 to iBIO’s Educate Center to help fund STEM programs for girls and solidifies its partnership with the association to support Illinois as a growing life sciences hub.
While last month saw many pharma executives leaving their positions to head towards smaller biotech companies, this month saw members of the industry climbing the ladder from various different starting points.
We will not stand behind non-competitive pricing schemes that undermine the incentive to innovate and invest in drug development, says BIO VP of industry research, David Thomas.
Lonza Pharma & Biotech will expand two of its manufacturing sites to reach the capabilities necessary to produce compounds bio-conjugates through to commercialization.
Think of big biotech hubs in the US and two areas will immediately come to mind: Boston, on the east coast, and San Francisco, on the west – Los Angeles wants to change that.
BioProcess International has kicked off at Biotech Week Boston. BioPharma-Reporter is here to cover the best of the sessions and the reactions from everyone present.
The Testa BioProcess Innovation Center in Sweden will help academics, startups, and biopharmaceutical companies secure industrial proof-of-concepts quicker, and with less cost, says GE Healthcare.
The bulk of biotech companies are firmly rooted towards the foot of
the ladder of corporate evolution. Precious few can realistically
claim to be at the top end of the evolutionary scale with full
R&D capabilities, global reach...
